Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection
Ann Oncol
.
2017 Mar 1;28(3):441-443.
doi: 10.1093/annonc/mdx016.
Authors
G Curigliano
1
,
A Goldhirsch
2
Affiliations
1
Giuseppe Curigliano and Carmen Criscitiello, Istituto Europeo di Oncologia, Milano, Italy.
2
European Institute of Oncology, Milan, Italy.
PMID:
28426119
DOI:
10.1093/annonc/mdx016
No abstract available
Publication types
Editorial
Comment
MeSH terms
Antibodies, Monoclonal, Humanized*
Breast Neoplasms*
Humans
Patient Selection
Trastuzumab
Substances
Antibodies, Monoclonal, Humanized
pertuzumab
Trastuzumab